FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062302016> ?p ?o ?g. }

• W2062302016 endingPage "1636" @default.
• W2062302016 startingPage "1629" @default.
• W2062302016 abstract "BACKGROUND The objective of this study was to determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) and daily oral thalidomide in patients with metastatic renal cell carcinoma (RCC). METHODS Between June, 2000 and January, 2001, 21 patients with metastatic RCC were enrolled onto this multi-institutional Phase II study of gemcitabine at 600 mg/m2 per day on Days 1, 8, and 15; 5-FU at 150 mg/m2 per day by continuous IV infusion through a permanent catheter on Days 1–21; and oral thalidomide on Days 1–28 starting at a dose of 200 mg daily. After the first 2 weeks of therapy, the thalidomide dose was escalated by 100 mg per day every week to a maximum dose of 400 mg per day unless it was precluded by toxicity. Treatment cycles were repeated every 28 days. RESULTS A high rate of venous thromboembolism (VTE) was observed. Five patients developed deep vein thrombosis (DVT), three patients developed pulmonary embolization (PE), and one patient suffered a fatal cardiac arrest preceded by hemoptysis, for an overall VTE rate of 43%. Of the 18 assessable patients, there were no complete responses and 2 partial responses (objective response rate, 10%; 95% confidence interval, 1–30%). CONCLUSIONS The addition of thalidomide to gemcitabine and 5-FU did not improve the objective response rate previously observed with gemcitabine and 5-FU alone and added significant vascular toxicity. The authors recommend against further development or use of this three-drug regimen. Cancer 2002;95:1629–36. © 2002 American Cancer Society. DOI 10.1002/cncr.10847" @default.
• W2062302016 created "2016-06-24" @default.
• W2062302016 creator A5007018215 @default.
• W2062302016 creator A5014285115 @default.
• W2062302016 creator A5025529463 @default.
• W2062302016 creator A5032869739 @default.
• W2062302016 creator A5059219836 @default.
• W2062302016 creator A5088131964 @default.
• W2062302016 date "2002-10-03" @default.
• W2062302016 modified "2023-10-12" @default.
• W2062302016 title "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma" @default.
• W2062302016 cites W1942932003 @default.
• W2062302016 cites W1980934541 @default.
• W2062302016 cites W1985147506 @default.
• W2062302016 cites W1985658104 @default.
• W2062302016 cites W1994276424 @default.
• W2062302016 cites W2006502477 @default.
• W2062302016 cites W2014824627 @default.
• W2062302016 cites W2016220220 @default.
• W2062302016 cites W2021374170 @default.
• W2062302016 cites W2022943800 @default.
• W2062302016 cites W2029409133 @default.
• W2062302016 cites W2038741107 @default.
• W2062302016 cites W2041881143 @default.
• W2062302016 cites W2042774683 @default.
• W2062302016 cites W2044889252 @default.
• W2062302016 cites W2059972525 @default.
• W2062302016 cites W2069334882 @default.
• W2062302016 cites W2078007924 @default.
• W2062302016 cites W2100184560 @default.
• W2062302016 cites W2125962958 @default.
• W2062302016 cites W2127206962 @default.
• W2062302016 cites W2139248078 @default.
• W2062302016 cites W2143813821 @default.
• W2062302016 cites W2222720953 @default.
• W2062302016 cites W2284629536 @default.
• W2062302016 cites W2316160054 @default.
• W2062302016 cites W4247650177 @default.
• W2062302016 doi "https://doi.org/10.1002/cncr.10847" @default.
• W2062302016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12365009" @default.
• W2062302016 hasPublicationYear "2002" @default.
• W2062302016 type Work @default.
• W2062302016 sameAs 2062302016 @default.
• W2062302016 citedByCount "108" @default.
• W2062302016 countsByYear W20623020162012 @default.
• W2062302016 countsByYear W20623020162013 @default.
• W2062302016 countsByYear W20623020162014 @default.
• W2062302016 countsByYear W20623020162015 @default.
• W2062302016 countsByYear W20623020162016 @default.
• W2062302016 countsByYear W20623020162017 @default.
• W2062302016 countsByYear W20623020162018 @default.
• W2062302016 countsByYear W20623020162020 @default.
• W2062302016 countsByYear W20623020162021 @default.
• W2062302016 countsByYear W20623020162023 @default.
• W2062302016 crossrefType "journal-article" @default.
• W2062302016 hasAuthorship W2062302016A5007018215 @default.
• W2062302016 hasAuthorship W2062302016A5014285115 @default.
• W2062302016 hasAuthorship W2062302016A5025529463 @default.
• W2062302016 hasAuthorship W2062302016A5032869739 @default.
• W2062302016 hasAuthorship W2062302016A5059219836 @default.
• W2062302016 hasAuthorship W2062302016A5088131964 @default.
• W2062302016 hasConcept C126322002 @default.
• W2062302016 hasConcept C126894567 @default.
• W2062302016 hasConcept C141071460 @default.
• W2062302016 hasConcept C2776364478 @default.
• W2062302016 hasConcept C2776694085 @default.
• W2062302016 hasConcept C2779609412 @default.
• W2062302016 hasConcept C2780258809 @default.
• W2062302016 hasConcept C2780456651 @default.
• W2062302016 hasConcept C29730261 @default.
• W2062302016 hasConcept C31760486 @default.
• W2062302016 hasConcept C71924100 @default.
• W2062302016 hasConcept C90924648 @default.
• W2062302016 hasConceptScore W2062302016C126322002 @default.
• W2062302016 hasConceptScore W2062302016C126894567 @default.
• W2062302016 hasConceptScore W2062302016C141071460 @default.
• W2062302016 hasConceptScore W2062302016C2776364478 @default.
• W2062302016 hasConceptScore W2062302016C2776694085 @default.
• W2062302016 hasConceptScore W2062302016C2779609412 @default.
• W2062302016 hasConceptScore W2062302016C2780258809 @default.
• W2062302016 hasConceptScore W2062302016C2780456651 @default.
• W2062302016 hasConceptScore W2062302016C29730261 @default.
• W2062302016 hasConceptScore W2062302016C31760486 @default.
• W2062302016 hasConceptScore W2062302016C71924100 @default.
• W2062302016 hasConceptScore W2062302016C90924648 @default.
• W2062302016 hasIssue "8" @default.
• W2062302016 hasLocation W20623020161 @default.
• W2062302016 hasLocation W20623020162 @default.
• W2062302016 hasOpenAccess W2062302016 @default.
• W2062302016 hasPrimaryLocation W20623020161 @default.
• W2062302016 hasRelatedWork W1604979917 @default.
• W2062302016 hasRelatedWork W1977727607 @default.
• W2062302016 hasRelatedWork W1991292752 @default.
• W2062302016 hasRelatedWork W2033082527 @default.
• W2062302016 hasRelatedWork W2118940674 @default.
• W2062302016 hasRelatedWork W2140023433 @default.
• W2062302016 hasRelatedWork W2167571882 @default.
• W2062302016 hasRelatedWork W2401639250 @default.

• next